Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

被引：10

作者：

Feun, LG ^{[1
]}

O'Brien, C ^{[1
]}

Molina, E ^{[1
]}

Rodriguez, M ^{[1
]}

Jeffers, L ^{[1
]}

Schiff, ER ^{[1
]}

Marini, A ^{[1
]}

Savaraj, N ^{[1
]}

Ardalan, B ^{[1
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Miami, FL 33152 USA

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2003年 / 129卷 / 01期

关键词：

5FUDR; interferon; doxorubicin; hepatocellular carcinoma;

D O I：

10.1007/s00432-002-0398-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m(2) subcutaneously followed in 2 h by doxorubicin 20 mg/m(2) intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.

引用

页码：17 / 20

页数：4

共 30 条

[1]

ARDALAN B, 1999, P ASCO, V8, pA249

[2]

ARDALAN B, 1996, P AN M AM SOC CLIN, V15, P202

[3]

BENSON AB, 1999, P AN M AM SOC CLIN, V18, pA256

[4]

BOUCHER EJ, 2001, P AN M AM SOC CLIN, V20, pA167

[5]

A PHASE-II TRIAL OF RECOMBINANT LEUKOCYTE INTERFERON PLUS DOXORUBICIN IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA [J].

FEUN, LG ;

SAVARAJ, N ;

HUNG, SE ;

REDDY, R ;

JEFFERS, L ;

BENEDETTO, P ;

LIVINGSTONE, AS ;

ARDALAN, B ;

LEVI, JU ;

PARKER, T ;

SCHIFF, ER .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (05) :393-395

[6]

FONG Y, 2001, PRINCIPLES PRACTICE

[7]

PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA RECEIVING SYSTEMIC CHEMOTHERAPY - IDENTIFICATION OF 2 GROUPS OF PATIENTS WITH PROSPECTS FOR PROLONGED SURVIVAL [J].

IHDE, DC ;

MATTHEWS, MJ ;

MAKUCH, RW ;

MCINTIRE, KR ;

EDDY, JL ;

SEEFF, LB .

AMERICAN JOURNAL OF MEDICINE, 1985, 78 (03) :399-406

[8]

Jiang WQ, 1997, CLIN CANCER RES, V3, P395

[9]

KODA J, 2001, P AN M AM SOC CLIN, V20, pA168

[10]

LAI CL, 1984, HEPATOLOGY, V4, P1015

← 1 2 3 →